Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 11/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.42 |
| ▸ | CCR1 | P32246 | 3/20 | 0.42 |
| ▸ | DDT | P30046 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL561233 | 0.84 | ELANE (0.52) | ELANECCR1DDT | |
| SCHEMBL31490267 | 0.84 | ELANE (0.52) | ELANECCR1DDT | |
| SCHEMBL561813 | 0.84 | ELANE (0.51) | ELANECCR1 | |
| SCHEMBL31490174 | 0.83 | ELANE (0.52) | ELANEMAPTNOTUM | |
| SCHEMBL561111 | 0.83 | ELANE (0.52) | ELANEMAPTNOTUM | |
| SCHEMBL561729 | 0.81 | CHRNB2 (0.55) | ELANENOTUMCCR1 | |
| SCHEMBL31490289 | 0.81 | ELANE (0.60) | ELANEMAPTALDH1A1CCR1DDT | |
| SCHEMBL561082 | 0.81 | ELANE (0.60) | ELANEMAPTALDH1A1CCR1DDT | |
| SCHEMBL560993 | 0.81 | CNR2 (0.52) | ELANEALDH1A1NOTUMCCR1 | |
| SCHEMBL31490248 | 0.81 | CNR2 (0.52) | ELANEALDH1A1NOTUMCCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063073-B2 | 2-pyridone derivatives as neutrophil elastase inhibitors and their use | ASTRAZENECA AB (SE) | 2011-11-22 | — | — | US | disclosed |
| US-20070203129-A1 | 2-Pyridone Derivatives As Neutrophil Elastase Inhibitors And Their Use | ASTRAZENECA AB (SE) | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203129-A1 | 2-Pyridone Derivatives As Neutrophil Elastase Inhibitors And Their Use | SERPINB1, ELANE, SERPINE1 | ELANE 2/4885MEN1 3811/4885CYP1A2 309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.